Antiplatelet and Anticoagulation Therapy in Structural Heart Disease Interventions Beyond TAVI

Manolis Vavuranakis; Konstantinos Dean Boudoulas; Ourania Katsarou; Dimitrios A Vrachatis; Konstantinos I Kalogeras; Theodore G Papaioannou; Gerasimos Siasos; Evangelos Oikonomou; George Lazaros; Michael-Andreas Vavuranakis; Spyridon Deftereos; Dimitrios Tousoulis

doi:10.2174/1381612822666161221143416

Antiplatelet and Anticoagulation Therapy in Structural Heart Disease Interventions Beyond TAVI

Curr Pharm Des. 2017;23(9):1328-1333. doi: 10.2174/1381612822666161221143416.

Affiliations

¹ 13 Astypaleas, Anoixi, Attiki 14569, Greece.
² Department of Cardiovascular Medicine, Ohio State University, Columbus, OH, United States.
³ Department of Cardiology, Hippokration Hospital, National and Kapodistrian University of Athens, Athens, Greece.
⁴ Department of Cardiology, Attikon Hospital, National and Kapodistrian University of Athens, Athens, Greece.

PMID: 28003014
DOI: 10.2174/1381612822666161221143416

Abstract

Transcatheter interventions for structural heart disease represent an emerging field in interventional cardiology. Undoubtedly, there is an absolute necessity for antiplatelet and/or anticoagulation treatment prior, during and post such interventions. However, currently administered regimens are mainly based in expert consensus recommendations. In the present review we aim to summarize data regarding anti platelet and/or anticoagulation treatment in the following transcatheter structural heart interventions: left atrial appendage closure, atrial septal defect closure, patent foramen oval closure, paravalvular leak closure.

Keywords: ASD; LAA; NOAC; PFO; antiplatelet; coumadin; transcatheter; warfarin.

Publication types

Review

MeSH terms

Anticoagulants / therapeutic use*
Heart Diseases / drug therapy*
Heart Diseases / surgery*
Humans
Platelet Aggregation Inhibitors / therapeutic use*
Transcatheter Aortic Valve Replacement*

Substances

Anticoagulants
Platelet Aggregation Inhibitors